company background image
TCON logo

TRACON Pharmaceuticals NasdaqCM:TCON Stock Report

Last Price

US$0.43

Market Cap

US$20.9m

7D

10.4%

1Y

-76.2%

Updated

26 Mar, 2024

Data

Company Financials +

TRACON Pharmaceuticals, Inc.

NasdaqCM:TCON Stock Report

Market Cap: US$20.9m

TRACON Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TRACON Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.43
52 Week HighUS$2.19
52 Week LowUS$0.13
Beta0.79
1 Month Change158.88%
3 Month Change134.97%
1 Year Change-76.24%
3 Year Change-94.47%
5 Year Change-97.47%
Change since IPO-99.54%

Recent News & Updates

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

Aug 10

TRACON Pharmaceuticals announces $5M registered direct offering

Dec 29

TRACON Pharma launches $8.8M direct offering

Dec 22

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

Shareholder Returns

TCONUS BiotechsUS Market
7D10.4%-0.5%0.6%
1Y-76.2%9.6%29.5%

Return vs Industry: TCON underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: TCON underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is TCON's price volatile compared to industry and market?
TCON volatility
TCON Average Weekly Movement25.7%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TCON's share price has been volatile over the past 3 months.

Volatility Over Time: TCON's weekly volatility has increased from 21% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200417Charles Theuerhttps://www.traconpharma.com

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.

TRACON Pharmaceuticals, Inc. Fundamentals Summary

How do TRACON Pharmaceuticals's earnings and revenue compare to its market cap?
TCON fundamental statistics
Market capUS$20.93m
Earnings (TTM)-US$3.59m
Revenue (TTM)US$12.05m

1.6x

P/S Ratio

-5.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TCON income statement (TTM)
RevenueUS$12.05m
Cost of RevenueUS$12.28m
Gross Profit-US$232.00k
Other ExpensesUS$3.36m
Earnings-US$3.59m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.079
Gross Margin-1.93%
Net Profit Margin-29.79%
Debt/Equity Ratio0%

How did TCON perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.